Skip to main content
. 2022 Mar 25;14(7):1681. doi: 10.3390/cancers14071681
AML acute myeloid leukaemia
APCs antigen-presenting cells
BCR B-cell receptor
Bregs regulatory B cells
CAF cancer-associated fibroblasts
CRC colorectal cancer
CSCs cancer stem cells
CTLs cytotoxic T lymphocytes/CD8+ T lymphocytes/CD8+ T cells
DAMPs damage-associated molecular patterns
DCs dendritic cells
ECM extracellular matrix
EGF epidermal growth factor
ICI immune checkpoint inhibitor
IDO indoleamine 2,3-dioxygenase
IFN Interferon
IIC infiltrating immune cells
IL Interleukin
ILCs innate lymphoid cells
IR immune response
IS immune system
LTis lymphoid-tissue inducer cells
MCs mast cells
MDSCs myeloid-derived suppressor cells
MHC-I/-II major histocompatibility complex-I/-II
NK cells natural killer cells
NSCLC non-small-cell lung cancer
PAMPs pathogen-associated molecular patterns
PDAC pancreatic ductal adenocarcinoma
PD-1 programmed cell death protein 1
PGE2 prostaglandin E2
ROS/RNS reactive oxygen species/reactive nitrogen species
SCC squamous cell carcinoma
TCR T-cell receptor
TGF transforming growth factor
Th T helper/CD4+ T lymphocytes/CD4+ T cells
TIL B cells tumour-infiltrating B cells
TLRs toll-like receptors
TME tumour microenvironment
TNF tumour necrosis factor
Treg regulatory T cells
VEGF endothelial growth factor